Protein-nanoparticle conjugates as potential therapeutic agents for the treatment of hyperlipidemia

Nanotechnology

Volumn 21, Issue 26, 2010, Pages

  Maximov, V D ^a   Reukov, V V ^a   Barry, J N ^a   Cochrane, C ^b   Vertegel, A A ^a  

^a South   (United States)

^b South Carolina Governor's School for Science and Mathematics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEINS; EXPERIMENTAL CONDITIONS; HEPATOCYTES; HYPERLIPIDEMIA; IN-VITRO; KUPFFER CELLS; LOW DENSITY LIPOPROTEIN RECEPTORS; MACROPHAGE CELL LINE; NANOPARTICLE CONJUGATE; POLY LACTIDE; POLYMERIC NANOPARTICLES; THERAPEUTIC AGENTS;

ANTIBODIES; CELL CULTURE; LIVER; MACROPHAGES;

NANOPARTICLES;

ANTIBODY; APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN; NANOPARTICLE; POLYESTER; POLYLACTIDE;

ANIMAL; ARTICLE; ATOMIC FORCE MICROSCOPY; CELL CULTURE; CELL DEATH; CELL SURVIVAL; CONFOCAL MICROSCOPY; CYTOLOGY; DRUG EFFECT; FLUORESCENCE MICROSCOPY; HUMAN; HYPERLIPIDEMIA; IMMUNOLOGY; LIGHT; MACROPHAGE; METABOLISM; MOUSE; PARTICLE SIZE; RADIATION SCATTERING; TIME; TITRIMETRY; ULTRASTRUCTURE;

ANIMALS; ANTIBODIES; APOLIPOPROTEIN B-100; CELL DEATH; CELL SURVIVAL; CELLS, CULTURED; HUMANS; HYPERLIPIDEMIAS; LIGHT; LIPOPROTEINS, LDL; MACROPHAGES; MICE; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; PARTICLE SIZE; POLYESTERS; SCATTERING, RADIATION; TIME FACTORS; TITRIMETRY;

EID: 77953520219     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/21/26/265103     Document Type: Article

References (24)

1. Lusis A J 2000 Atherosclerosis Nature 407 233-41
2. Patel R P, Moellering D, Murphy-Ullrich J, Jo H, Beckman J S and Darley-Usmar V M 2000 Cell signaling by reactive nitrogen and oxygen species in atherosclerosis Free Rad. Biol. Med. 28 1780-94
3. Choy P C, Siow Y L, Mymin D and Karmin O 2004 Lipids and atherosclerosis Biochem. Cell Biol. 82 212-24
4. Saini H K, Arneja A S and Dhalla N S 2004 Role of cholesterol in cardiovascular dysfunction Can. J. Cardiol. 20 333-46
5. Skalen K, et al. 2002 Subendothelial retention of atherogenic lipoproteins in early atherosclerosis Nature 417 750-4
6. Wilson P W, Garrison R J, Castelli W P, Feinleib M, McNamara P M and Kannel W B 1980 Prevalence of coronary heart-disease in the framingham offspring study-role of lipoprotein cholesterols Am. J. Cardiol. 46 649-54
7. De Backer G, et al. 2003 European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts, Sept. 2003) Eur. Heart J. 24 1601-10
8. Kent S M, Coyle L C, Flaherty P J, Markwood T T and Taylor A J 2004 Mared low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis Clin. Cardiol. 27 17-21
9. Rosamond W, et al. 2007 Heart disease and stroke statistics 2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation (December 2007) 1-122
10. Tikkanen M J, Helve E and Nikkila E A 1987 Treatment of familial and nonfamilial hypercholesterolemia-a review of Hmg-Coa reductase inhibitors and probucol Eur. Heart J. 8 97-101
11. Goldstein J L and Brown M S 1987 Regulation of low-density-lipoprotein receptors-implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis Circulation 76 504-7
12. Jones P, Kafonek S, Laurora I and Hunninghake D 1998 Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the curves study) Am. J. Cardiol. 81 582-7 (Pubitemid 28182422)
13. Abramson J and Wright J M 2007 Are lipid-lowering guidelines evidence-based? Lancet 369 168-9
14. Alsheikh-Ali A A, Maddukuri P V, Han H and Karas R H 2007 Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials J. Am. College Cardiol. 50 409-18
15. Eriksson M, Carlson L A, Miettinen T A and Angelin B 1999 Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans Circulation 100 594-8
16. Thaxton C S, Daniel W, Giljohann D A, Thomas A D and Mirkin C A 2009 Templated spherical high density lipoprotein nanoparticles J. Am. Chem. Soc. 131 1384-5
17. Cheng J, et al. 2007 Formulation of functionalized PLGA-PEG nanoparticles for invivo targeted drug delivery Biomaterials 28 869-76
18. Buchmueller K L, Hill B T, Platz M S and Weeks K M 2003 RNA-tethered phenyl azide photocrosslinking via a short-lived indiscriminant electrophile J. Am. Chem. Soc. 125 10850-61
19. Schrock A K and Schuster G B 1984 Photochemistry of phenyl azide: chemical properties of the transient intermediates J. Am. Chem. Soc. 106 5228-34
20. Hook F, Rodahl M, Brzezinski P and Kasemo B 1998 Energy dissipation kinetics for protein and antibody-antigen adsorption under shear oscillation on a quartz crystal microbalance Langmuir 14 729-34
21. American Heart Association Report (cited 2010 April 28) available from www.americanheart.org/presenter.jhtml?identifier = 183
22. Yokoyama H 1952 Regeneration of mouse liver after partial hepatectomy Cancer Res. 13 80
23. Crofton R W, Diesselhoff-den Dulk M M C and van Furth R 1978 The origin, kinetics, and characteristics of the Kurffer cells in the normal steady state J. Exp. Med. 148 1-17
24. Smith A and Hunneyball I M 1986 Evaluation of poly(lactic acid) as a biodegradable drug delivery system for parenteral administration Int. J. Pharmaceut. 30 215-20